TargetBeta
ABL1
ABL proto-oncogene 1, non-receptor tyrosine kinase · also JTK7, c-ABL, p150, ABL · SH2 domain containing
7 programs in company-led studies act on ABL1, from 5 companies: 2 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| asciminibrule | Novartis | phase 4 | 167 running | BCR | ChEMBL |
| regorafenibrule | Bayer | phase 4 | 404 running | BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | ChEMBL |
| imatinibrule | Novartis | phase 4 | 703 running | BCR, KIT, PDGFRB | ChEMBL |
| nilotinibrule | Novartis | phase 4 | 571 running | BCR | ChEMBL |
| olverembatinibrule | Ascentage Pharma Group International | phase 3 | 105 running | BCR, EPHB2 | ChEMBL |
| Embibatinib | Hansoh Pharmaceutical Group | phase 3 | 75 running | BCR | the company's pipeline |
| TQB3911 | Sino Biopharmaceutical | phase 1 | 11 running | BCR | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 6 programs
- Leukemia, Myeloid, Chronic-Phase, 5 programs
- Gastrointestinal Stromal Tumors, 3 programs
- Neoplasms, 2 programs
- Bronchiolitis Obliterans Syndrome, 1 program
- Carcinoma, Hepatocellular, 1 program
- Colorectal Neoplasms, 1 program
- Glioblastoma, 1 program
- Leukemia, 1 program
- Leukemia, Myeloid, Accelerated Phase, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2027Embibatinib · Hansoh Pharmaceutical Group · phase 3 · NCT07933224
- Mar 31, 2027olverembatinib · Ascentage Pharma Group International · phase 3 · NCT06640361
- Sep 3, 2027asciminib · Novartis · phase 4 · NCT04925479
- Sep 30, 2027regorafenib · Bayer · phase 4 · NCT02955940
- Oct 2027imatinib · Novartis · phase 4 · NCT07406633
- Aug 30, 2030nilotinib · Novartis · phase 4 · NCT04877522
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.